Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12352749 | 0.79 | CYP2A6 (0.42) | — | |
| SCHEMBL270865 | 0.78 | KIF11 (0.49) | KIF11 | |
| SCHEMBL270345 | 0.77 | XDH (0.47) | KIF11XDH | |
| SCHEMBL19736786 | 0.76 | PRMT5 (0.39) | — | |
| SCHEMBL762270 | 0.75 | PTK2 (0.50) | — | |
| SCHEMBL13765812 | 0.75 | CYP11B2 (0.32) | KIF11 | |
| SCHEMBL25601809 | 0.75 | KIF11 (0.31) | KIF11 | |
| SCHEMBL31357013 | 0.75 | CYP1A1 (0.46) | — | |
| SCHEMBL19728983 | 0.75 | IDO1 (0.39) | KIF11 | |
| SCHEMBL13043925 | 0.72 | RXRB (0.36) | XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10842791-B2 | Small molecule inhibitors of EGFR and PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-11-24 | — | — | US | disclosed |
| US-20190167686-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-06-06 | — | — | US | disclosed |
| US-10206924-B2 | Small molecule inhibitors of EGFR and PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-02-19 | — | — | US | disclosed |
| US-20170360788-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10206924-B2 | Small molecule inhibitors of EGFR and PI3K | EGFR, ERBB2, ERBB3 | KIF11 3653/4885XDH 4160/4885 |
| US-20170360788-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | EGFR, ERBB2, ERBB3 | KIF11 3653/4885XDH 4160/4885 |
| US-10842791-B2 | Small molecule inhibitors of EGFR and PI3K | EGFR, ERBB2, ERBB3 | KIF11 3653/4885XDH 4160/4885 |
| US-20190167686-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | EGFR, ERBB2, ERBB3 | KIF11 3653/4885XDH 4160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.